Estimating neutralising antibody responses against emerging SARS-CoV-2 variants utilising convalescent sera before the roll-out of XBB-lineage vaccines

IF 4.5 3区医学 Q2 IMMUNOLOGY Vaccine Pub Date : 2025-02-20 DOI:10.1016/j.vaccine.2025.126898

Ana Atti , Anna England , Julia Sung , Sarah Foulkes , Jasmin Islam , Ashley Otter , Kelly Thomas , Bassam Hallis , Susan Hopkins , Sue Charlton , Victoria Hall

{"title":"Estimating neutralising antibody responses against emerging SARS-CoV-2 variants utilising convalescent sera before the roll-out of XBB-lineage vaccines","authors":"Ana Atti , Anna England , Julia Sung , Sarah Foulkes , Jasmin Islam , Ashley Otter , Kelly Thomas , Bassam Hallis , Susan Hopkins , Sue Charlton , Victoria Hall","doi":"10.1016/j.vaccine.2025.126898","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>SARS-CoV-2 immune escape variants can alter existing vaccine effectiveness. In September 2023, we aimed to predict the neutralising response against BA.2.86 offered by XBB-lineage vaccines before vaccine roll-out utilising XBB.1.5 convalescent sera. We then assessed the response to XBB-lineage boosters from different individuals in the same cohort.</div></div><div><h3>Methods</h3><div>A total of 78 sera samples (pre/post-XBB.1.5 infection and pre/post-XBB-lineage vaccination) were tested for live microneutralisation against SARS-CoV-2 Victoria and Omicron subvariants. Geometric means (GM) of neutralising antibody titres (nAbT) pre- and post-infection/vaccination were compared.</div></div><div><h3>Results</h3><div>After XBB.1.5 infection, a 4-fold increase in neutralising antibody titres against BA.2.86 was observed compared to pre-infection titres (GM 51 vs 210, <em>p</em> ≤ 0.0001). A similar increase in BA.2.86 nAbT was seen post-XBB-lineage vaccination (GM 144 vs 600, fold change = 4.17, p ≤ 0.0001).</div></div><div><h3>Conclusion</h3><div>XBB.1.5 infection was a suitable proxy to predict the neutralisation response following XBB-lineage vaccination. Our findings may support future vaccine development and vaccination strategies.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"51 ","pages":"Article 126898"},"PeriodicalIF":4.5000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X25001951","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

SARS-CoV-2 immune escape variants can alter existing vaccine effectiveness. In September 2023, we aimed to predict the neutralising response against BA.2.86 offered by XBB-lineage vaccines before vaccine roll-out utilising XBB.1.5 convalescent sera. We then assessed the response to XBB-lineage boosters from different individuals in the same cohort.

Methods

A total of 78 sera samples (pre/post-XBB.1.5 infection and pre/post-XBB-lineage vaccination) were tested for live microneutralisation against SARS-CoV-2 Victoria and Omicron subvariants. Geometric means (GM) of neutralising antibody titres (nAbT) pre- and post-infection/vaccination were compared.

Results

After XBB.1.5 infection, a 4-fold increase in neutralising antibody titres against BA.2.86 was observed compared to pre-infection titres (GM 51 vs 210, p ≤ 0.0001). A similar increase in BA.2.86 nAbT was seen post-XBB-lineage vaccination (GM 144 vs 600, fold change = 4.17, p ≤ 0.0001).

Conclusion

XBB.1.5 infection was a suitable proxy to predict the neutralisation response following XBB-lineage vaccination. Our findings may support future vaccine development and vaccination strategies.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.